Holen Sie sich die Stockscreener-App
25.11
0.20%
-0.05
Handel nachbörslich:
25.12
0.01
+0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Starboard Value Ramps Up Its Bet On Salesforce And Pfizer - Finimize
Starboard Value's Strategic Play in Big Pharma: A Critical Evaluation of the Pfizer Turnaround Thesis - AInvest
Starboard Value raises stake in Pfizer and Salesforce, cuts in News Corp - MarketScreener
Ligand Announces Closing of Convertible Senior Notes Offering - GlobeNewswire Inc.
FDA signals it may revoke approval of Pfizer's pediatric COVID vaccine, leaving kids fewer options - FOX 17 West Michigan News
Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: A Market Game-Changer? - TipRanks
Pfizer’s Phase 3 Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis Treatment - TipRanks
Pfizer’s VICTORIE Study: A Deep Dive into Anticoagulant Use in Cancer Patients - TipRanks
Pfizer’s New Migraine Treatment Study: A Potential Game-Changer for Young Patients - TipRanks
Pfizer’s MagnetisMM-32 Study: A New Hope for Multiple Myeloma Treatment - TipRanks
Pfizer’s MagnetisMM-4 Study: A New Horizon in Multiple Myeloma Treatment - TipRanks
Pfizer’s Rimegepant Study: Evaluating Pregnancy Outcomes - TipRanks
Pfizer’s Ritlecitinib Study: A New Hope for Alopecia Areata Treatment - TipRanks
Pfizer’s Promising Phase 3 Study on Elranatamab for Multiple Myeloma - TipRanks
Pfizer’s Promising Phase 2 Study on PF-06823859 for Lupus Treatment - TipRanks
Pfizer’s FLOTILLA Study: Continuing Cancer Treatment Access - TipRanks
Pfizer’s New Study on Rimegepant: A Potential Game-Changer for Menstrual Migraine Prevention - TipRanks
Pfizer’s 20vPnC Vaccine Study: A Key Step in Expanding Safety Profiles - TipRanks
Pfizer’s Promising Phase 3 Study on Colorectal Cancer Treatment - TipRanks
Pfizer’s New Study on Marstacimab: A Potential Game-Changer for Hemophilia A Treatment - TipRanks
Pfizer’s Latest Clinical Study on Abrocitinib for Pediatric Eczema: Key Insights for Investors - TipRanks
Eli Lilly and Pfizer’s Innovative Approach in Metastatic Colorectal Cancer Study - TipRanks
If You Invested $10K In Pfizer Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
Stock Analysis | Pfizer OutlookA Weak Technical Picture Amid Mixed Analyst Signals - AInvest
FDA may revoke Pfizer COVID-19 shot for young, healthy children. - Yahoo News Canada
FDA could make it harder to get young kids a COVID shot - The Hill
Not for Granted: Pediatric Immunization Through Experts’ Lens - Pfizer
Pfizer Stock Is Making Moves On Promising Cancer Data. It Is Now A Buy? - Investor's Business Daily
Pfizer (PFE) Reports Promising Phase 3 Results For Bladder Cancer Treatment Combination - simplywall.st
Why is Pfizer Inc. stock going upMarket Movers & Weekly Breakout Stock Alerts - 선데이타임즈
Pfizer says FDA may pull its Covid vaccine for young children - Endpoints News
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
Pfizer’s Rimegepant Study: A New Hope for Migraine Prevention in Japan - TipRanks
Pfizer’s Latest Study on HER2-positive Breast Cancer: Key Insights for Investors - TipRanks
Pfizer’s New Cancer Study: A Potential Game Changer? - TipRanks
FDA may pull authorization for Pfizer COVID shot for kids under 5 - The Hill
Pfizer’s Zavegepant Study: A New Hope for Migraine Relief in Asia - TipRanks
Should You Now Consider Selling Your Pfizer (PFE) Shares Before its Too Late? - Yahoo Finance
Cantor Fitzgerald maintains Neutral rating on Pfizer stock at $24 price target - Investing.com
FDA may revoke Pfizer COVID-19 vaccine authorization for kids under certain age - Fox Business
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB - Yahoo Finance
3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer - Yahoo Finance
The Top 5 Analyst Questions From Pfizer’s Q2 Earnings Call - Yahoo Finance
Pfizer Stock Surges on Revised Earnings Guidance as $850M Trading Volume Ranks 117th Amid Valuation Discount to Peers - AInvest
Pfizer/BioNTech may not win FDA renewal for pediatric COVID shot: report - MSN
Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study - insights.citeline.com
FDA may pull authorization of Pfizer's Covid vaccine for children under 5, company says - CNBC
Pfizer (PFE) Reports Positive Phase 3 Results In Bladder Cancer Treatment Study - simplywall.st
Pfizer Raises Its Guidance And Analysts Up Their TargetsPFE Stock Looks Cheap - Barchart.com
The Zacks Analyst Blog Highlights Pfizer, Novo Nordisk and Eli Lilly - The Globe and Mail
Pfizer looks to expand ADC use after positive bladder cancer data - BioPharma Dive
Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: Key Insights for Investors - TipRanks
Pfizer and Astellas Pharma’s Prostate Cancer Study: A Potential Game-Changer? - TipRanks
Pfizer’s New Study on Inotuzumab Ozogamicin: A Potential Game-Changer in Pediatric Leukemia Treatment - TipRanks
Pfizer’s MagnetisMM-4 Study: A New Hope for Multiple Myeloma Treatment - TipRanks
Pfizer In Spotlight As FDA Reportedly Mulls Withdrawing Authorization For COVID-19 Vaccine For Kids Under 5 - Stocktwits
BlinkRx’s Ties to Donald Trump Jr. Questioned Amid Pfizer and Elicio Therapeutics’ Cancer Research Updates - geneonline.com
Former Pfizer Chief Scientific Officer joins MC Sciences as Independent Chairman - Yahoo Finance
Implications of Potential Pfizer Pediatric Vaccine Withdrawal on the U.S. Immunization Market - AInvest
Ascites Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company - The Globe and Mail
Pfizer's combination therapy improves survival in bladder cancer trial - Reuters
Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business - simplywall.st
Statutory Profit Doesn't Reflect How Good Pfizer's (NYSE:PFE) Earnings Are - Yahoo Finance
FDA Weighs Pulling Pfizer’s Covid Vaccine for Kids Under Age 5 - Bloomberg.com
Pfizer’s combination therapy improves survival in bladder cancer trial - PharmaLive
Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancer - Seeking Alpha
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda - Yahoo Finance
Pfizer and Merck's Bladder Cancer Breakthrough: A Paradigm Shift in Oncology and a Win for Shareholders? - AInvest
0.93%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):